An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin Following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients With Advanced Soft Tissue Sarcoma

Trial Profile

An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin Following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients With Advanced Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Olaratumab (Primary) ; Olaratumab (Primary) ; Doxorubicin; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Apr 2016 Pharmacokinetics, safety and drug-drug interaction results (n=15) were presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 15 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
    • 21 Jan 2016 Number of treatment arms changed from 2 to 4 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top